Peramivir Anhydrous

Summary

Peramivir Anhydrous (CHEMBL139367) is an approved small-molecule antiviral drug (ATC J05AH03); indicated across 2 conditions including viral infectious disease and influenza.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J05AH03
• Indications: 2 conditions
• Clinical trials: 15
• Chemistry: 328.41 Da · C15H28N4O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL139367
Name	Peramivir Anhydrous
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	154234
ChEBI	CHEBI:85202
ATC	J05AH03
Molecular formula	C15H28N4O4
Molecular weight	328.41
InChIKey	XRQDFNLINLXZLB-CKIKVBCHSA-N

SMILES: CCC(CC)[C@@H]([C@H]1[C@@H](C[C@@H]([C@H]1O)C(=O)O)N=C(N)N)NC(=O)C

IUPAC name: (1S,2S,3S,4R)-3-[(1S)-1-acetamido-2-ethylbutyl]-4-(diaminomethylideneamino)-2-hydroxycyclopentane-1-carboxylic acid

ChEBI definition: A member of the class of guanidines that is used (as its trihydrate) for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days.

Pharmacological roles (ChEBI): antiviral drug, EC 3.2.1.18 (exo-α-sialidase) inhibitor.

Also known as: Peramivir anhydrous, RWJ-270201, Peramivir, peramivir, PERAMIVIR ANHYDROUS, PERAMIVIR TRIHYDRATE, PERAMIVIR, Peramivir Trihydrate, Peramivir; Rapivab

Parent form; salt/anhydrous children: CHEMBL3989402

Patent coverage: 95 distinct patent families (227 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Neuraminidase, Neuraminidase, Neuraminidase, Sialidase-2, Neuraminidase, Sialidase, Neuraminidase.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P03470	9.4	IC50	0.4	nM	CHEMBL_ACT_18700468
P03470	9.32	IC50	0.48	nM	CHEMBL_ACT_18700434
Q9IGQ6	9.08	Ki	0.83	nM	CHEMBL_ACT_7958200
P03468	8.85	IC50	1.4	nM	CHEMBL_ACT_113312
P03471	8.7	IC50	2	nM	CHEMBL_ACT_18700480
Q9IGQ6	8.47	IC50	3.4	nM	CHEMBL_ACT_7958195
P03474	8.3	IC50	5	nM	CHEMBL_ACT_699439
P03474	7.96	IC50	11	nM	CHEMBL_ACT_113313

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
viral infectious disease	4	MONDO:0005108	EFO:0000763
influenza	3	MONDO:0005812	EFO:0007328

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE3	7
PHASE2	4
PHASE4	1
PHASE2/PHASE3	1
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02609399	PHASE4	COMPLETED	ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir
NCT00486980	PHASE3	WITHDRAWN	Intramuscular Peramivir for the Treatment of Uncomplicated Influenza
NCT00610935	PHASE3	TERMINATED	Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza
NCT00957996	PHASE3	COMPLETED	Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
NCT00958776	PHASE3	TERMINATED	A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza
NCT01224795	PHASE3	TERMINATED	A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.
NCT02369159	PHASE3	COMPLETED	Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza
NCT02635724	PHASE3	COMPLETED	Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
NCT02665351	PHASE2/PHASE3	COMPLETED	Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections
NCT05648448	PHASE2	RECRUITING	A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
NCT00419263	PHASE2	COMPLETED	Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.
NCT00453999	PHASE2	COMPLETED	Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza
NCT00705406	PHASE2	COMPLETED	A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza
NCT01063933	PHASE1/PHASE2	WITHDRAWN	Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza
NCT00297050	PHASE1	COMPLETED	Safety and Dose Study of Peramivir for Influenza Treatment

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).